Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
01.07. | Revelation Biosciences to implement 1-for-3 reverse stock split | 1 | Investing.com | ||
01.07. | Revelation Biosciences plant Aktienzusammenlegung im Verhältnis 1:3 | 1 | Investing.com Deutsch | ||
REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
01.07. | Revelation Biosciences, Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 | 92 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of... ► Artikel lesen | |
25.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
04.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
29.05. | Revelation Biosciences sets terms for $4 million public offering | 3 | Investing.com | ||
28.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
23.05. | Revelation Biosciences board member steps down amid new focus | 2 | Investing.com | ||
23.05. | REVELATION BIOSCIENCES, INC. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
20.05. | REVELATION BIOSCIENCES, INC. - S-1, General form for registration of securities | 2 | SEC Filings | ||
09.05. | Revelation Biosciences GAAP EPS of -$2.11 | 1 | Seeking Alpha | ||
08.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
10.04. | Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? | 1 | Insider Monkey | ||
17.03. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
06.03. | REVELATION BIOSCIENCES, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
24.02. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
24.02. | Revelation Biosciences gets continued listing approval from Nasdaq | 2 | Seeking Alpha | ||
11.02. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,275 | +0,94 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
EVOTEC | 7,104 | +0,82 % | Evotec-Aktie: 5 Euro oder 10 Euro? Das sollten Anleger jetzt wissen! | © Foto: Bild von Rudolfs Klintsons auf PexelsDie Evotec-Aktie stürzt ab, während der Biotech-Sektor brummt. Der einstige Star aus Hamburg lieferte schwache Zahlen, verunsichert Anleger und sorgt mit... ► Artikel lesen | |
BIONTECH | 94,85 | -1,51 % | Mehr als 50% Upside? Wenn die BioNTech-Aktie DAS schafft, ist alles möglich | So gut wie jetzt war die Aktie von BioNTech schon seit Wochen nicht mehr unterwegs. Aber einen Meilenstein könnte das Papier mittelfristig noch erreichen - und dann ist vieles möglich. Langsam aber... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,610 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 25,420 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,280 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
PROKIDNEY | 3,720 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 19,570 | 0,00 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
COGENT BIOSCIENCES | 11,100 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
NUVALENT | 84,73 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
BEAM THERAPEUTICS | 21,150 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
MODERNA | 28,145 | -1,45 % | Der Anteilsschein von Moderna läuft prima: Große Kursgewinne! (27,015 €) | Die Aktie von Moderna zählt heute zu den großen Gewinnern an der Börse. Der Titel verteuert sich am Dienstag deutlich. Zu den auffälligsten Papieren an der US-amerikanischen Börse gehört heute die Aktie... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 41,620 | +6,23 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
ARCELLX | 69,86 | +1,28 % | Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study | ||
IMMUNOVANT | 18,590 | +2,48 % | Goldman Sachs nimmt Berichterstattung über Immunovant mit "Neutral"-Rating wieder auf |